Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-10-05 pm EDT
2.560 USD   -3.76%
09/28Lyell Immunopharma Names Rahsaan W. Thompson Chief Legal Officer
MT
09/20Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/12Gritstone Bio Says Cancer Immunotherapies Showed 'Early Evidence of Efficacy' in Phase 1/2 Study; Shares Rise
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

08/15/2022 | 04:05pm EDT

Gritstone bio, Inc. announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published on August 15, 2022 in Nature Medicine. The paper, “Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results,” details results demonstrating that GRANITE generated strong, persistent, and functional tumor-specific CD4+ and CD8+ T cell responses that have potential broad applicability across a range of disease settings. The published data were originally presented at the European Society for Medical Oncology (ESMO) Congress 2021, and acted as the basis for launching two randomized, controlled studies of GRANITE, including a Phase 2/3 trial that has registrational intent (GRANITE-CRC-1L).

Since initiation of the Phase 1/2 study, Gritstone has followed study participants and observed increased overall survival (OS) in colorectal cancer (CRC) patients who demonstrated a molecular response (measured by a reduction in circulating tumor DNA [ctDNA] levels from baseline) versus those who did not. As of May 2022, median OS of this subgroup (treated third-line CRC patients who demonstrated a molecular response) exceeded 18 months with the median not yet reached. This compares to median OS of 7.8 months for patients who did not demonstrate a molecular response, results which are generally consistent with extensive prior data from patients receiving various third-line therapies.

Baseline characteristics of these two patient populations are similar. The Phase 1/2 study remains ongoing. GRANITE is now being evaluated in two randomized studies in earlier-stage disease; 1) GRANITE-CRC-1L (NCT05141721), a Phase 2/3 trial in newly diagnosed metastatic, microsatellite-stable colorectal cancer (MSS-CRC) that has registrational intent.

The first patient was treated in this study in July 2022, and initial results from this study are expected in the second half of 2023. 2) GRANITE-ADJUVANT (NCT05456165), a phase 2 study in patients with high-risk stage II/III colon cancer who are ctDNA+ after definitive surgery. Gritstone's neoantigen-based immunotherapies are engineered to elicit a significant T cell response (particularly CD8+ cytotoxic T cells) against mutation-derived tumor-specific neoantigens (TSNA), that Gritstone identifies using its proprietary artificial intelligence platform, EDGE™.

GRANITE is an individualized neoantigen-based immunotherapy and uses a priming adenoviral vector (GRT-C901) and self-amplifying mRNA vector (GRT-R902) to deliver personalized immunotherapy containing the relevant neoantigens. GRANITE was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of MSS-CRC.


© S&P Capital IQ 2022
All news about GRITSTONE BIO, INC.
09/28Lyell Immunopharma Names Rahsaan W. Thompson Chief Legal Officer
MT
09/20Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/12Gritstone Bio Says Cancer Immunotherapies Showed 'Early Evidence of Efficacy' in Phase ..
MT
09/12Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Trea..
AQ
09/12Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Pat..
CI
09/01Gritstone to Participate in Two Upcoming Investor Conferences
AQ
08/22Goldman Sachs Downgrades Gritstone bio to Sell From Neutral; Price Target is $2
MT
08/17Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANI..
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study..
CI
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 19,2 M - -
Net income 2022 -123 M - -
Net cash 2022 23,0 M - -
P/E ratio 2022 -1,66x
Yield 2022 -
Capitalization 187 M 187 M -
EV / Sales 2022 8,53x
EV / Sales 2023 13,6x
Nbr of Employees 193
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 2,56 $
Average target price 11,33 $
Spread / Average Target 343%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Executive VP & Head-Research & Development
Erin E. Jones Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-80.09%194
CSL LIMITED-1.14%90 052
SAMSUNG BIOLOGICS CO.,LTD.-10.63%40 706
BIOGEN INC.9.07%38 810
WUXI BIOLOGICS (CAYMAN) INC.-47.81%26 225
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 439